Home Cart Sign in  
Chemical Structure| 1384426-12-3 Chemical Structure| 1384426-12-3

Structure of NT157
CAS No.: 1384426-12-3

Chemical Structure| 1384426-12-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NT157

CAS No. :1384426-12-3
Formula : C16H14BrNO5S
M.W : 412.26
SMILES Code : S=C(NCC1=CC(O)=C(O)C(O)=C1)/C=C/C2=CC(O)=C(O)C(Br)=C2
MDL No. :MFCD28127272

Safety of NT157

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Related Pathways of NT157

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT-116 cells 3 µM 20 minutes NT157 inhibited STAT3 phosphorylation Oncogene. 2016 May 19;35(20):2634-44
MC-38 cells 3 µM 24 hours NT157 inhibited IGF-1-induced ERK1/2 and AKT phosphorylation Oncogene. 2016 May 19;35(20):2634-44
Cholinergic neurons 10 µM 2 hours NT157 inhibits IRS1 and AKT phosphorylation, blocking NGF's activation of the insulin signaling pathway Mol Neurobiol. 2019 Jan;56(1):535-552
MPC5 cells 2 µM 2 hours NT157 treatment significantly reversed the protective effects of DOP on HG-treated MPC5 cells, showing markedly decreased glucose consumption, increased MDA production, reduced phosphorylation of IRS-1 and AKT, and increased DNA damage. Aging (Albany NY). 2023 Oct 8;15(19):10291-10306
MEL-20-06-039 1 and 2.5 µM 24 and 48 hours RPPA protein profiling showed changes in PI3K/AKT pathway Cancers (Basel). 2022 Dec 19;14(24):6247
MM28 1 and 2.5 µM 24 and 48 hours RPPA protein profiling showed changes in PI3K/AKT pathway Cancers (Basel). 2022 Dec 19;14(24):6247
MEL270 1 and 2.5 µM 24 and 48 hours RPPA protein profiling showed changes in PI3K/AKT pathway Cancers (Basel). 2022 Dec 19;14(24):6247
CAF cells 3 µM 24 hours NT157 inhibited IGF-1-induced αSMA expression and collagen type I production Oncogene. 2016 May 19;35(20):2634-44
SET2 cells 0.2, 0.4, 0.8, 1.6, 3.2 µM 24, 48, 72 hours At high concentrations (3.2 μM), NT157 significantly reduced cell viability and induced apoptosis Signal Transduct Target Ther. 2020 Jan 24;5(1):5
HEL cells 0.2, 0.4, 0.8, 1.6, 3.2 µM 24, 48, 72 hours NT157 significantly reduced cell viability, increased apoptosis, inhibited cell proliferation and clonogenicity, and caused G2/M phase cell cycle arrest Signal Transduct Target Ther. 2020 Jan 24;5(1):5
NCI-H460 1.6, 3.2, 6.4, 12.5, 25, 50, 100 µM 24, 48, 72 hours NT157 decreased cell viability in a time- and dose-dependent manner (p < 0.05). The IC50 ranged from 4.8 to 12.9 µM for H460 cells. Sci Rep. 2022 Oct 12;12(1):17092
NCI-H1299 1.6, 3.2, 6.4, 12.5, 25, 50, 100 µM 24, 48, 72 hours NT157 decreased cell viability in a time- and dose-dependent manner (p < 0.05). The IC50 ranged from 1.7 to 9.7 µM for H1299 cells. Sci Rep. 2022 Oct 12;12(1):17092
NCI-H1975 0.8, 1.6 µM 48 hours NT157 in combination with gefitinib presented potentiating effects in the reduction of cell viability of H1975 cells. Sci Rep. 2022 Oct 12;12(1):17092
MP41 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 µM 72 hours NT157 dose-dependent decrease in cell survival Cancers (Basel). 2022 Dec 19;14(24):6247
MP65 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 µM 72 hours NT157 dose-dependent decrease in cell survival Cancers (Basel). 2022 Dec 19;14(24):6247
92.1 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 µM 72 hours NT157 dose-dependent decrease in cell survival Cancers (Basel). 2022 Dec 19;14(24):6247
MEL202 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 µM 72 hours NT157 dose-dependent decrease in cell survival Cancers (Basel). 2022 Dec 19;14(24):6247
MM28 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 µM 72 hours NT157 dose-dependent decrease in cell survival Cancers (Basel). 2022 Dec 19;14(24):6247
MP46 0.05, 0.1, 0.25, 0.5, 1.0, 2.5 µM 72 hours NT157 dose-dependent decrease in cell survival Cancers (Basel). 2022 Dec 19;14(24):6247
U-2OS 0.3–3 µM 72 hours Evaluate the inhibitory effect of NT157 on U-2OS cell proliferation, showing dose-dependent growth inhibition. Front Endocrinol (Lausanne). 2015 May 13;6:74
OS-19 0.3–3 µM 72 hours Evaluate the inhibitory effect of NT157 on OS-19 cell proliferation, showing dose-dependent growth inhibition. Front Endocrinol (Lausanne). 2015 May 13;6:74
MG-63 0.3–3 µM 72 hours Evaluate the inhibitory effect of NT157 on MG-63 cell proliferation, showing dose-dependent growth inhibition. Front Endocrinol (Lausanne). 2015 May 13;6:74

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Chicken Chicken chorioallantoic membrane (CAM) model Topical application 1 µM Daily for 4 days NT157 treatment reduces UM tumor growth Cancers (Basel). 2022 Dec 19;14(24):6247
Balb/c mice Methylated bovine serum albumin-immunised mice Subcutaneous injection 10 mg/kg Mice were monitored daily throughout the experiment and sacrificed at the end (day 28) Inhibition of IGF1R signaling led to enlargement of the marginal zone, increased frequency of IgM+CD21+B cells, and enhanced autoantibody production Front Immunol. 2022 Aug 29;13:958206
Mice Autologous blood injection-induced ICH model Intraperitoneal injection 50 mg/kg Single dose, 1 hour before ICH To investigate the reversal effect of NT157 on the protective effects of ELP, results showed that NT157 reversed the neurobehavioral improvement and anti-inflammatory effects of ELP. J Cereb Blood Flow Metab. 2023 Jun;43(6):869-881
Mice CPC-APC mouse model Intraperitoneal injection 70 mg/kg Three times a week for 3-4 weeks NT157 significantly reduced tumor burden, inhibited cancer cell proliferation and induced apoptosis, while also inhibiting CAF activation and inflammation Oncogene. 2016 May 19;35(20):2634-44
Mice 4T1 mammary tumor model Intraperitoneal route 70 mg/kg Three times per week for 3 weeks NT157 significantly decreased the number of metastatic lung nodules in 4T1 tumor-bearing mice and decreased expression of ARG1, TGFβ1, and IL-10 in sorted Gr-1+CD11b+ myeloid cells Nat Commun. 2018 Jul 4;9(1):2611

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.43mL

0.49mL

0.24mL

12.13mL

2.43mL

1.21mL

24.26mL

4.85mL

2.43mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories